Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
STAb-T cells
- Development stage
- Preclinical
- Lead developer
- STAB Therapeutics
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, TCR-Engineered T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Tumor-Infiltrating Lymphocytes (TILs) → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
STAb-T cells (Secreted T-cell Engager Antibody T cells) are an adoptive cell therapy platform consisting of engineered T cells designed to secrete bispecific T-cell engager (BiTE) antibodies. Unlike conventional CAR-T cells that rely on membrane-bound receptors, STAb-T cells act as local "bio-factories" within the tumor microenvironment, delivering T-cell redirecting activity. This approach aims to overcome antigen heterogeneity and restricted effector engagement in solid tumors like melanoma. The secreted antibodies can recruit and activate both the engineered cells and endogenous "bystander" T cells to kill tumor cells. Research from the University of Manchester has demonstrated their efficacy in melanoma models targeting MCAM (Melanoma Cell Adhesion Molecule).
- Other names
- Secreted T-cell Engager Antibody T cells
02
Targets
MCAMCD3 (T-cell surface glycoprotein CD3)
Beyond the preview
Go deeper on STAb-T cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on STAb-T cells.